AB0675 COUNTRY COMPARISON ON THE IMPACT OF THE COVID-19 PANDEMIC ON PATIENTS WITH RHEUMATIC DISEASES. RESULTS FROM THE REUMAVID STUDY (PHASE 1)

Background: The COVID-19 pandemic has impacted every aspect of life European patients with rheumatic and musculoskeletal diseases (RMDs). Objectives: aim is to evaluate country differences on the impact first wave habits, healthcare access, health status, mental wellbeing in RMDs. Methods: REUMAVID an international collaboration led by Health & Territory Research group at University Seville, together a multidisciplinary team including patient organisations rheumatologists. This cross-sectional study consisting online survey gathering data from diagnosis 15 RMDs Cyprus, France, Greece, Italy, Portugal, Spain, United Kingdom. Participants were recruited (April-July 2020). Kruskal-Wallis χ 2 tests used analyse between countries independent variables. Results: 1,800 participated (REUMAVID). 37.8% Spanish increased their smoking consumption during followed Cyprus (32.1%) Portugal (31.0%), while alcohol was higher UK (36.3%) France (27.0%). 82.3% Spain unable attend appointment rheumatologist, either due cancellations or other personal reasons. Access primary care most limited where only 45.0% 51.6% got access. 61.9% Italy 53.3% experienced worsening pandemic. 68.5% 67.8% risk anxiety. highest proportion depression found Greece (55.4%), (55.1%), (54.8%). 66.9% reported poor wellbeing, compared 23.8% 30.1% (Table 1). Conclusion: related containment measures heterogeneously affected across countries, who overall harmful more difficulties accessing and, well-being. Table 1. Bivariate analysis (N=1,800, unless specified) Mean ± SD n (% ) n: 558 464 229 57 101 127 264 - Inflammatory arthritis 1 509 (91.2) 402 (86.6) 147 (64.2) 33 (57.9) (56.4) 89 (70.1) 120 (45.5) Fibromyalgia 53 (9.5) 14 (3.0) 26 (11.4) (24.6) 28 (27.7) (41.7) 124 (47.0) Connective tissue disease 36 (6.5) (3.2) 13 (5.7) 25 (43.9) (32.7) 30 (23.6) 61 (23.1) Osteoarthritis 140 (25.1) 29 (6.3) 102 (44.5) 0 (0.0) 8 (7.9) (11.8) (4.9) Osteoporosis 50 (9.0) 3 (0.6) 20 (8.7) (3.5) 9 (8.9) 18 (14.2) 12 (4.5) Vasculitis (1.6) (0.2) 6 (2.6) (5.3) 5 (3.9) (3.4) Sapho (only France) (6.6) Smoking, More than before. N= 556 16 (10.3) 48 (37.8) 22 (24.7) (23.5) (32.1) (20.5) (31.0) Alcohol consumption, 1,085 99 (36.3) 27 (27.0) 4 (7.0) (4.0) (13.3) 11 (18.3) Unable meet rheumatologist. 722 83 (48.8) 186 (82.3) (30.3) (64.3) (51.2) 77 (56.2) care. 689 87 (76.3) 65 (67.7) 32 (76.2) (60.9) 17 (60.7) (51.6) 117 (45.0) Change Much worse worse. N=1,786 214 (38.4) 245 (53.3) 98 (43.0) 24 (42.9) 38 78 (61.9) 135 (51.9) WHO-5. Poor well-being (≤50). 1,777 292 (52.5) 303 (66.9) 100 21 (37.5) 46 (46.5) (23.8) (30.1) Risk 1,769 241 (43.6) 309 (68.5) 118 (52.0) 31 (55.4) (62.2) 175 (67.8) depression. (33.6) 232 (51.4) 54 (55.1) 69 (54.8) 138 (53.8) Note: all relations significant 0.001 level. Including: Axial Spondyloarthritis, Rheumatoid Arthritis, Psoriatic Juvenile Idiopathic Gout Peripheral Spondyloarthritis; Systemic Lupus Erythematosus, Sjögren’s Syndrome, Sclerosis Myositis; Polymyalgia Rheumatic Arteritis. Acknowledgements: supported Novartis Pharma AG. We would like thank that completed as well including: League Against Rheumatism (CYPLAR) Association Française de Lutte Anti-Rhumatismale (AFLAR) Hellenic (ELEANA) Associazione Nazionale Persone con Malattie Reumatologiche e Rare (APMARR) Portuguese Diseases (LPCDR), Federation Spondyloarthritis Associations (CEADE), Patients’ Forum (FEP), UNiMiD, Rheumatology (LIRE), Andalusian (LIRA), Catalonia Galician National Society (NASS), Arthritis (NRAS) Action Disclosure Interests: Marco Garrido-Cumbrera: None declared, Helena Marzo-Ortega Speakers bureau: AbbVie, Biogen, Celgene, Janssen, Lilly, Novartis, Pfizer, Takeda UCB, Consultant of: Pfizer Grant/research support from: Janssen Laura Christen Employee AG, Loreto Carmona: José Correa-Fernández: Sergio Sanz-Gómez: Elsa Mateus Lilly Sanofi, Grünenthal S.A., MSD, Medac, Janssen-Cilag, Pharmakern, GAfPA., Souzi Makri GSK Bayer., Pedro Plazuelo-Ramos: LAURENT GRANGE: Serena Mingolla: KATY ANTONOPOULOU: Dale Webb Clare Jacklin Abbvie, Amgen, Eli Gilead, Roche, Sanofi Shantel Irwin: Victoria Navarro-Compán BMS, UCB